Kali Inc (OTCMKTS: KALY) Breakout Looms On Improving Fundamentals
April 04 2019 - 01:59PM
InvestorsHub NewsWire
Kali Inc (OTCMKTS: KALY) Breakout
Looms On Improving Fundamentals
April 4, 2019 -- InvestorsHub NewsWire -- Jim
Bloom -- Kali Inc (OTCMKTS:
KALY) resurgence is gathering pace as a spike in
trading volume continues to affirm renewed investor interest. The
stock has once again started surging after coming under immense
short selling pressure at the start of the year.
KALY SHARE PRICE ANALYSIS
The announcement that the company is developing cannabis
treatment for type 2 Diabetes is the latest catalyst fuelling the
upside action. The company has also set sights on the $600 million
cannabis beverage market with a new 25 mg CBD extract formulation,
as it continues to strengthen its product line.
In addition, the company has inked a strategic partnership
with Nouveau Life Pharmaceuticals Inc
(OTCMKTS:
NOUV) and Puration Inc (OTCMKTS:
PURA) as part of an effort of coming up with cannabis
pharmaceutical solutions. The trio has signed an agreement
with Generex Biotechnology
Corporation (OTCMKTS:
GNBT) as part of the drive.
Investors have continued to push the stock up, in response to
recent developments that affirm Kali-Extracts push for value in the
multi-billion sector. After plunging to the $0.01 mark, the stock
has once again started trending higher after powering through a
tight trading range.
If recent price action activity is anything to go by, then
Kali-Extracts could as well be on its way to 52-week highs of $0.03
mark. A rally followed by a close above the critical technical
level should open the door for the stock to continue powering high
on turning bullish.
ABOUT KALI-EXTRACTS
Kali-Extracts is a cannabis-focused company engaged in the
research and development of cannabis treatments. The company is
currently working on cannabis treatments for various therapies as
well as chronic pain. It also provides Pharmaceuticals with
cannabis extracts and health wellness products.
WHY IS KALI-EXTRACTS SURGING
Shares of Kali-Extracts are surging after a long period of
consolidation on the company announcing plans to pursue
opportunities in two multimillion industries. The company has
embarked on a research and development drive as it seeks to come up
with cannabis-infused treatments for addressing COPD and Type 2
Diabetes.
The new treatments will supplement the company’s pilot cannabis
treatment for Chronic Obstructive Pulmonary Disease. Success on the
development of cannabis treatments for addressing Type 2 Diabetes
should expand the company’s footprint into the $64 billion diabetes
market.
Even as the company continues to work on cannabis treatments, it
is also in the process of strengthening its pipeline of products.
Through a patented extraction process, the company has produced a
10mg formulation of Puration leading EVERx CBD sports product as it
moves to make its debut in the $600 million Cannabis Beverage
Market.
In addition to cannabis products development, Kaly also
continues to generate revenue from its patented cannabis extraction
processes.
Plans by Texas to remove hemp as a controlled substance is
another development that continues to shore, Kali, extracts
sentiments in the market. Such a move should enhance the company’s
push for opportunities in the state, especially with its cannabis
extraction lab.
“Just the type of market condition management is looking for
to support the implantation of the previously announced cannabis
extraction lab to be dedicated to the 100-acre hemp farm to be
operated by partner Nouveau (NOUV)
in Texas,” Kaly in a statement.
TEXAS OPPORTUNITY
The company has already inked a strategic partnership with
Nouveau as part of its push for opportunities in Texas. The two are
to join forces on the development of proprietary hemp cultivar
expected to enhance Kaley’s extract development.
Enhancing operations in Texas part of Kaley’s push for value in
the cannabis sector. The company has been exploring ways of
enhancing its sales channel in pursuit of additional revenue
streams. Early in the year, the company secured a $100,000
wholesale order for its Hemp4mula CBD infused Gummies.
BOTTOM LINE
Kaly’s share price does not provide an accurate reflection of
the company’s tremendous potential. The company has continued to
show how focused it is about pursuing opportunities with a
diversified product line.
Development of cannabis-infused treatments for addressing
various unmet medical needs provides clear evidence of how focused
the company is about securing its long-term prospects. The company
is also expanding its retail chain as it looks to generate optimum
returns from its product line as well as extraction lab.
Price gains in the market look set to be the order of the day,
on investors taking note of the tremendous opportunity at stake as
the company continues to refine its product line.
We will be updating our subscribers as soon as we know
more. For the latest updates on KALY, sign up below!
Disclosure: We have no position in any of the stocks
mentioned and have not been compensated for this article.
RELATED ITEMS:KALI INC, KALI INC. (OTCMKTS:KALY), OTCMKTS:KALY
Original Source https://insiderfinancial.com/
SOURCE: Jim Bloom
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2023 to Mar 2024